Dr. Byrd’s research accomplishments relate best to studies done between the laboratory and clinic (translational work) with several different therapeutic agents active in chronic lymphocytic leukemia (CLL) and related leukemias and lymphomas. His work has shown that therapeutic agents such as rituximab, TRU-16, flavopiridol, dinaciclib and the B-cell receptor kinase inhibitors (GS1101 and ibrutinib) are effective against CLL. In particular, Dr. Byrd has been and continues to be active in developing therapeutic antibodies and other targeted agents in his pursuit of non-toxic therapies for leukemia. The basic-science and clinical work of Dr. Byrd and his colleagues played a key role in the U.S. Food and Drug Administration’s February 2014 approval for expanding the use of ibrutinib to treat certain patients with CLL.
Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia.
Ventricular Arrhythmias Following Ibrutinib Initiation for Lymphoid Malignancies.
Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance).
Use of PD-1 (PDCD1) inhibitors for the treatment of Richter syndrome: experience at a single academic centre.
Non-covalent inhibition of C481S Bruton's tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib resistant CLL.
Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission.
Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials.
Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase using PROTAC-mediated Degradation.
Changes in clinical stage identify patients with CLL and different outcome within iwCLL partial response: RESONATE study.
Frequency and impact of grade three or four toxicities of novel agents on outcomes of older patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma (alliance A151611).
Guidelines for diagnosis, indications for treatment, response assessment and supportive management of chronic lymphocytic leukemia.
First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL.
Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials.
Single-Agent Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia: A 5-Year Experience.
Development of sub-100 femtosecond timing and synchronization system.
BRAFV600E accelerates disease progression and enhances immune suppression in a mouse model of B-cell leukemia.
Spotlight on Ibrutinib in PCNSL: Adding Another Feather to Its Cap.
Ibrutinib treatment improves T cell number and function in CLL patients.
Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials.
NF-?B p50 (nfkb1) contributes to pathogenesis in the Eµ-TCL1 mouse model of chronic lymphocytic leukemia.
PLCG2 C2 domain mutations co-occur with BTK and PLCG2 resistance mutations in chronic lymphocytic leukemia undergoing ibrutinib treatment.
The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia.
Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL.
The regulation of tumor-suppressive microRNA, miR-126, in chronic lymphocytic leukemia.
Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Ibrutinib in previously treated chronic lymphocytic leukemia patients with autoimmune cytopenias in the RESONATE study.
Mutational Landscape and Gene Expression Patterns in Adult Acute Myeloid Leukemias with Monosomy 7 as a Sole Abnormality.
Sweet-Like Eruption Associated With Obinutuzumab Therapy for Chronic Lymphocytic Leukemia.
Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.
Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT.
Chromosome abnormalities at onset of complete remission are associated with worse outcome in patients with acute myeloid leukemia and an abnormal karyotype at diagnosis: CALGB 8461 (Alliance).
A New Role for Lyn in the CLL Microenvironment.
A phase II study of two dose levels of ofatumumab induction followed by maintenance therapy in symptomatic, previously untreated chronic lymphocytic leukemia.
NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016.
A phase I trial of the intravenous Hsp90 inhibitor alvespimycin (17-DMAG) in patients with relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.
Lenalidomide Induces Interleukin-21 Production by T Cells and Enhances IL21-Mediated Cytotoxicity in Chronic Lymphocytic Leukemia B Cells.
Reprogramming Nurse-like Cells with Interferon ? to Interrupt Chronic Lymphocytic Leukemia Cell Survival.
A phase 1 clinical trial of flavopiridol consolidation in chronic lymphocytic leukemia patients following chemoimmunotherapy.
Hsp90 inhibition increases SOCS3 transcript and regulates migration and cell death in chronic lymphocytic leukemia.
Non-immunosuppressive FTY720-derivative OSU-2S mediates reactive oxygen species-mediated cytotoxicity in canine B-cell lymphoma.
Histone Deacetylase Inhibitors Enhance the Therapeutic Potential of Reovirus in Multiple Myeloma.
Chronic lymphocytic leukemia: recent progress and current challenges.
Proteomic characterization of circulating extracellular vesicles identifies novel serum myeloma associated markers.
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.
DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemia.
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
Daunorubicin-Loaded DNA Origami Nanostructures Circumvent Drug-Resistance Mechanisms in a Leukemia Model.
Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment.
Venetoclax Adds a New Arrow Targeting Relapsed CLL to the Quiver.
Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia.
Assessment of Promoter Methylation Identifies PTCH as a Putative Tumor-suppressor Gene in Human CLL.
Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma.
Therapeutic CD94/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia.
DNA Origami: Daunorubicin-Loaded DNA Origami Nanostructures Circumvent Drug-Resistance Mechanisms in a Leukemia Model (Small 3/2016).
Externally validated predictive clinical model for untreated del(17p13.1) chronic lymphocytic leukemia patients.
HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide.
Autologous hematopoietic stem cell transplant induces the molecular aging of T-cells in multiple myeloma.
Epigenetic silencing of miR-708 enhances NF-?B signaling in chronic lymphocytic leukemia.
BRAF(V600E) induces ABCB1/P-glycoprotein expression and drug resistance in B-cells via AP-1 activation.
Mass Cytometry: A High-Throughput Platform to Visualize the Heterogeneity of Acute Myeloid Leukemia.
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.
IGHV and Interphase Cytogenetics in a Patient With Chronic Lymphocytic Leukemia.
Introduction to a series of reviews on chronic lymphocytic leukemia.
Hypermorphic mutation of phospholipase C, ?2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation.
Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia.
Jumping translocations, a novel finding in chronic lymphocytic leukaemia.
CpG oligodeoxynucleotide CpG-685 upregulates functional interleukin-21 receptor on chronic lymphocytic leukemia B cells through an NF-?B mediated pathway.
Antagonizing ClpP: A New Power Play in Targeted Therapy for AML.
miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton's tyrosine kinase inhibition with Ibrutinib.
Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
Reduced occurrence of tumor flare with flavopiridol followed by combined flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL).
Granzyme B expression is enhanced in human monocytes by TLR8 agonists and contributes to antibody-dependent cellular cytotoxicity.
Response: Additional data needed for a better understanding of the potential relationship between atrial fibrillation and ibrutinib.
Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015.
Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia.
Somatic MED12 mutations are associated with poor prognosis markers in chronic lymphocytic leukemia.
Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK-STAT pathway in Sézary syndrome.
OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells.
Tetraspanins as therapeutic targets in hematological malignancy: a concise review.
Proteomic profiling identifies specific histone species associated with leukemic and cancer cells.
Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies.
Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997.
Phase I dose escalation trial of the novel proteasome inhibitor carfilzomib in patients with relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma.
Otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR(™) therapeutic protein, for relapsed or refractory NHL patients.
PrEMeR-CG: inferring nucleotide level DNA methylation values from MethylCap-seq data.
A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL.
New strategies in chronic lymphocytic leukemia: shifting treatment paradigms.
Mitochondrial priming of chronic lymphocytic leukemia patients associates Bcl-xL dependence with alvocidib response.
NF-?B functions in tumor initiation by suppressing the surveillance of both innate and adaptive immune cells.
Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician.
Circulating miRNA markers show promise as new prognosticators for multiple myeloma.
A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemia.
Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia.
The B-cell receptor pathway: a critical component of healthy and malignant immune biology.
Impact of targeted therapy on outcome of chronic lymphocytic leukemia patients with relapsed del(17p13.1) karyotype at a single center.
Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia.
Targeting Interleukin-2-Inducible T-cell Kinase (ITK) in T-Cell Related Diseases.
Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-d, as therapy for previously treated indolent non-Hodgkin lymphoma.
Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110d, for relapsed/refractory chronic lymphocytic leukemia.
A phase 1 study of the PI3Kd inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL).
Ocaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia.
Auranofin induces lethal oxidative and endoplasmic reticulum stress and exerts potent preclinical activity against chronic lymphocytic leukemia.
Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002.
Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity.
Evolution of DNA methylation is linked to genetic aberrations in chronic lymphocytic leukemia.
A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia.
Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL).